What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at HC Wainwright issued their FY2024 EPS estimates for shares of Sarepta Therapeutics in a research note issued to investors on Monday, November 25th. HC Wainwright analyst M. Kapoor expects that the biotechnology company will post earnings of $2.30 per share for the year. HC Wainwright currently has a “Sell” rating and a $80.00 target price on the stock. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.07 per share. HC Wainwright also issued estimates for Sarepta Therapeutics’ Q4 2024 earnings at $1.53 EPS, Q1 2025 earnings at $2.32 EPS, Q2 2025 earnings at $2.69 EPS, Q3 2025 earnings at $2.75 EPS, Q4 2025 earnings at $2.82 EPS and FY2025 earnings at $10.58 EPS.

A number of other research firms have also recently issued reports on SRPT. Citigroup lowered their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and boosted their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Robert W. Baird reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Royal Bank of Canada reissued an “outperform” rating and issued a $182.00 target price on shares of Sarepta Therapeutics in a research note on Monday, October 21st. Finally, Guggenheim raised their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $176.73.

Sarepta Therapeutics Trading Up 13.8 %

Shares of SRPT opened at $130.50 on Wednesday. The stock’s 50-day moving average price is $121.80 and its 200 day moving average price is $131.40. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The firm has a market capitalization of $12.47 billion, a price-to-earnings ratio of 104.40 and a beta of 0.81. Sarepta Therapeutics has a 12-month low of $78.67 and a 12-month high of $173.25.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of SRPT. Tidal Investments LLC grew its holdings in Sarepta Therapeutics by 8.5% during the 1st quarter. Tidal Investments LLC now owns 2,902 shares of the biotechnology company’s stock worth $376,000 after acquiring an additional 228 shares during the period. Castleark Management LLC bought a new stake in Sarepta Therapeutics in the first quarter valued at about $304,000. Comerica Bank lifted its stake in Sarepta Therapeutics by 489.4% in the first quarter. Comerica Bank now owns 3,336 shares of the biotechnology company’s stock valued at $432,000 after buying an additional 2,770 shares during the period. New Covenant Trust Company N.A. bought a new position in Sarepta Therapeutics during the first quarter worth about $32,000. Finally, Farallon Capital Management LLC grew its position in shares of Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares during the period. 86.68% of the stock is owned by institutional investors.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the transaction, the chief financial officer now directly owns 33,946 shares in the company, valued at approximately $4,662,822.56. This represents a 14.99 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.70% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.